RETRACTED: Correlations of mouse lymphoma xenografts with the expressions of MMP-9 and Bcl-2 (Retracted Article)

被引:0
作者
Shi, C. -L. [1 ]
Zhang, X. -Y. [1 ]
Li, Y. [1 ]
Song, L. -L. [1 ]
Wang, L. [1 ]
机构
[1] Qingdao Ctr Hosp, Dept Hematol, Qingdao, Shandong, Peoples R China
关键词
Lymphoma; MMP-9; BCL-2; FAMILY PROTEINS; SURVIVAL; GROWTH; CELLS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To establish a mouse lymphoma xenograft model so as to investigate the correlation between the expression of matrix metallopeptidase-9 (MMP-9) and that of B-cell lymphoma 2 (Bcl-2) in lymphomas. MATERIALS AND METHODS: Diffuse large Bcl (DLBCL) cells were cultured, and a mouse lymphoma xenograft model was established via the subcutaneous injection. Mouse lymphoma tissues were extracted, and the expressions of MMP-9 and Bcl-2 messenger ribonucleic acids (mRNAs) in the xenograft tumor were detected using Real-time polymerase chain reaction (PCR). lmmunohistochemistry was used to detect the expression levels of MMP-9 and Bcl-2 proteins in lymphoma tissues and tumor-adjacent tissues. The consistency of MMP-9 expression and Bcl-2 expression was analyzed via Spearman's rank correlation analysis. RESULTS: The expressions of MMP-9 and Bcl-2 in lymphoma tissues were increased. The expression levels of MMP-9 and Bcl-2 proteins in lymphoma tissues were higher than those in tumor-adjacent tissues. The expression levels of MMP-9 and Bcl-2 were correlated with the body weight loss degree of mice, and the expression of MMP-9 was positively associated with that of BCL-2 in lymphomas. CONCLUSIONS: MMP-9 and Bcl-2 are associated with the onset of DLBCL, and they are potential impact factors affecting the prognosis.
引用
收藏
页码:1176 / 1183
页数:8
相关论文
共 23 条
  • [1] [Anonymous], 2012, Molecular Imaging and Contrast Agent Database (MICAD) Internet
  • [2] [Anonymous], J CLIN INVEST
  • [3] Cheng H, 2017, EUR REV MED PHARMACO, V21, P1471
  • [4] BCL-2 family proteins: Critical checkpoints of apoptotic cell death
    Danial, Nika N.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (24) : 7254 - 7263
  • [5] Haeffner A, 1999, EUR J IMMUNOL, V29, P334, DOI 10.1002/(SICI)1521-4141(199901)29:01<334::AID-IMMU334>3.0.CO
  • [6] 2-S
  • [7] NODULAR LYMPHOMA - EVIDENCE FOR ORIGIN FROM FOLLICULAR-B LYMPHOCYTES
    JAFFE, ES
    SHEVACH, EM
    FRANK, MM
    BERARD, CW
    GREEN, I
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1974, 290 (15) : 813 - 819
  • [8] Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets
    Karube, K.
    Enjuanes, A.
    Dlouhy, I.
    Jares, P.
    Martin-Garcia, D.
    Nadeu, F.
    Ordonez, G. R.
    Rovira, J.
    Clot, G.
    Royo, C.
    Navarro, A.
    Gonzalez-Farre, B.
    Vaghefi, A.
    Castellano, G.
    Rubio-Perez, C.
    Tamborero, D.
    Briones, J.
    Salar, A.
    Sancho, J. M.
    Mercadal, S.
    Gonzalez-Barca, E.
    Escoda, L.
    Miyoshi, H.
    Ohshima, K.
    Miyawaki, K.
    Kato, K.
    Akashi, K.
    Mozos, A.
    Colomo, L.
    Alcoceba, M.
    Valera, A.
    Carrio, A.
    Costa, D.
    Lopez-Bigas, N.
    Schmitz, R.
    Staudt, L. M.
    Salaverria, I.
    Lopez-Guillermo, A.
    Campo, E.
    [J]. LEUKEMIA, 2018, 32 (03) : 675 - 684
  • [9] Matalliotakis M, 2017, J BUON, V22, P1603
  • [10] Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
    Merino, Delphine
    Khaw, Seong L.
    Glaser, Stefan P.
    Anderson, Daniel J.
    Belmont, Lisa D.
    Wong, Chihunt
    Yue, Peng
    Robati, Mikara
    Phipson, Belinda
    Fairlie, Walter D.
    Lee, Erinna F.
    Campbell, Kirsteen J.
    Vandenberg, Cassandra J.
    Cory, Suzanne
    Roberts, Andrew W.
    Ludlam, Mary J. C.
    Huang, David C. S.
    Bouillet, Philippe
    [J]. BLOOD, 2012, 119 (24) : 5807 - 5816